Karyopharm has a month left to salvage its cancer expansion plans
A commercial-stage cancer drugmaker with a market cap about one-third the size of its projected 2026 revenues is on the brink of defaulting. Karyopharm Therapeutics said Thursday that it has until ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.